Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status

BJOG. 2011 Jun;118(7):814-24. doi: 10.1111/j.1471-0528.2011.02920.x. Epub 2011 Mar 10.

Abstract

Objective: To compare surgical outcomes and occult cancer rates at risk-reducing salpingo-oophorectomy in BRCA carriers and high-risk women who had not undergone genetic testing.

Design: Prospective cohort study.

Setting: Tertiary high-risk familial gynaecological cancer clinic.

Population: Women undergoing risk-reducing salpingo-oophorectomy between January 2005 and November 2009.

Methods: Women at high-risk of ovarian/tubal cancer were identified on the basis of the inclusion criteria for the UK Familial Ovarian Cancer Screening Study. Risk management options discussed with 1456 high-risk women included risk-reducing salpingo-oophorectomy. A strict histopathological protocol with serial slicing was used to assess tubes and ovaries.

Results: In total, 308 high-risk women (191 with unknown mutation status; 117 known BRCA1/BRCA2 carriers) chose risk-reducing surgery; 94.5% of procedures were performed laparoscopically. The surgical complication rate was 3.9% (95% CI 2.0-6.7). Four ovarian and ten tubal occult invasive/in situ cancers were found. The overall occult invasive cancer rate was 5.1% (95% CI 1.9-10.83) in BRCA1/BRCA2 carriers and 1.05% (95% CI 0.13-3.73) in untested women. When tubal in situ cancers were included, the overall rate was 4.55% (95% CI 2.5-7.5). Two untested women with tubal carcinoma in situ were subsequently found to be BRCA carriers. The median ages of BRCA carriers (58 years; IQR 13.4 years) and untested women (49.5 years; IQR 20.6 years) with occult invasive/in situ cancer were not significantly different (P = 0.454).

Conclusions: Both high-risk women of unknown mutation status and BRCA carriers have a significant (although higher in the latter group) rate of occult invasive/in situ tubal/ovarian cancer, with a similar age distribution at detection. The data has important implications for counselling high-risk women on the likelihood of occult malignancy and perioperative complications at risk-reducing salpingo-oophorectomy. Women with occult disease should be offered genetic testing.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / genetics
  • Carcinoma in Situ / genetics
  • Carcinoma in Situ / pathology
  • Carcinoma in Situ / prevention & control*
  • Carcinoma in Situ / surgery
  • Fallopian Tube Neoplasms / genetics
  • Fallopian Tube Neoplasms / pathology
  • Fallopian Tube Neoplasms / prevention & control*
  • Fallopian Tube Neoplasms / surgery
  • Female
  • Genes, BRCA1*
  • Genes, BRCA2*
  • Genetic Testing
  • Heterozygote
  • Hospitals, University
  • Humans
  • Incidence
  • Laparoscopy
  • Middle Aged
  • Mutation*
  • Neoplasm Invasiveness
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / prevention & control*
  • Ovarian Neoplasms / surgery
  • Ovariectomy*
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Salpingectomy*
  • Treatment Outcome

Substances

  • Biomarkers, Tumor